Get the Stockscreener App
90.17
0.18%
-0.16
Pre-market:
89.83
-0.34
-0.38%
Boston Scientific Corp stock is traded at $90.17, with a volume of 4.51M.
It is down -0.18% in the last 24 hours and up +2.38% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$90.33
Open:
$90.81
24h Volume:
4.51M
Relative Volume:
0.83
Market Cap:
$132.22B
Revenue:
$15.91B
Net Income/Loss:
$1.79B
P/E Ratio:
109.96
EPS:
0.82
Net Cash Flow:
$1.89B
1W Performance:
+1.58%
1M Performance:
+2.38%
6M Performance:
+19.65%
1Y Performance:
+65.57%
1-Day Range:
$89.47
$90.81
1-Week Range:
$86.01
$91.08
52-Week Range:
$53.93
$91.08
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BSX | 90.17 | 132.22B | 15.91B | 1.79B | 1.89B | 0.82 |
| ABT | 115.93 | 201.34B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 385.68 | 146.32B | 21.97B | 3.59B | 3.21B | 6.74 |
| MDT | 84.11 | 107.39B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 69.54 | 41.01B | 6.60B | 4.16B | 490.10M | 2.34 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio - Insider Monkey
Boston Scientific Co. (NYSE:BSX) Stake Boosted by PNC Financial Services Group Inc. - MarketBeat
Boston Scientific Stock Set to Gain From Completion of Axonics Deal - Yahoo Finance
Boston Sci study shows Watchman Flx better OPTION than DOAC - BioWorld Online
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific Completes $3.7B Acquisition of Axonics - Orange County Business Journal
Boston Scientific stock soars to all-time high of $89.33 - Investing.com
Boston Scientific stock soars to all-time high of $89.33 By Investing.com - Investing.com Canada
Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today - Yahoo Finance
Boston Scientific’s Watchman could be new option for patients post ablation: study - Yahoo Finance
Boston Scientific acquires Axonics - Medical Buyer
Boston Scientific reports outcomes from trial of LAAC device - Yahoo Finance
Boston Scientific to Acquire Cortex - Today's Medical Developments
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial - Quantisnow
Boston Scientific (BSX) Completes Acquisition of Axonics - GuruFocus.com
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific put volume heavy and directionally bearish - TipRanks
Boston Scientific Closes $3.7B Deal for Axonics - MPO-mag
Boston Scientific Closes Acquisition of Axonics, Inc. - Quantisnow
Boston Scientific Closes Acquisition of Axonics, Inc. – Company Announcement - Financial Times
Boston Scientific closes $3.7B Axonics deal after lengthy review - Yahoo Finance
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
SoniVie Names Axonics' Raymond Cohen as Chairman Following $3.7B Boston Scientific Deal | BSX Stock News - StockTitan
Boston Scientific Co. (NYSE:BSX) Shares Bought by Huntington National Bank - MarketBeat
Investing in Boston Scientific (NYSE:BSX) three years ago would have delivered you a 113% gain - Yahoo Finance
Urology Devices Market to Surpass Market Valuation of USD 61.62 Billion by 2031 | SkyQuest Technology - Benzinga
Boston Scientific EVP John Sorenson sells $2.68m in stock - Investing.com
Boston Sci charges ahead with AVANT GUARD PFA trial - BioWorld Online
Boston Scientific To Present At 2024 UBS Global Healthcare Conference; Webcast At 10:15 AM ET - Nasdaq
Boston Scientific resumes enrolment in pulsed field ablation trial - Yahoo Finance
BSXBoston Scientific Corp. Latest Stock News & Market Updates - StockTitan
Boston Scientific Corporation (BSX): Among the Best Low Volatility Stocks to Invest In Now - Insider Monkey
Boston Scientific Corporation (BSX): A Hot Growth Stock to Buy According to Hedge Funds - Insider Monkey
Van ECK Associates Corp Has $5.06 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
8 Hot Growth Stocks To Buy According to Hedge Funds - Insider Monkey
Boston Scientific stock soars to all-time high of $88.81 - Investing.com
We Think Boston Scientific's (NYSE:BSX) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Petri Dish: Boston Scientific resumes atrial fibrillation trial; Seaport hires CFO - The Business Journals
Boston Scientific CEO sells shares worth $13.8 million By Investing.com - Investing.com Canada
Boston Scientific CEO sells shares worth $13.8 million - Investing.com
Boston Scientific Corp. stock rises Thursday, still underperforms market - MarketWatch
Boston Scientific (BSX) Resumes AVANT GUARD Clinical Trial for A - GuruFocus.com
Boston Scientific resumes AVANT GUARD trial - Investing.com
Kidney Stone Management Market Forecast Report, 2024-2032Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share - Yahoo Finance
Boston Scientific Resumes AVANT GUARD Clinical Trial - TipRanks
Boston Scientific Corp. stock rises Wednesday, still underperforms market - MarketWatch
Boston Scientific Corp. stock rises Tuesday, still underperforms market - MarketWatch
Boston Scientific to Speak at Conference - Baystreet.ca
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference – Company Announcement - Financial Times
Boston Scientific to bolster cardiac ablation portfolio with Cortex acquisition - Medical Device Network
Heritage Investors Management Corp Sells 7,684 Shares of Boston Scientific Co. (NYSE:BSX) - MarketBeat
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):